What is ENDRA Life Sciences Price-to-Operating-Cash-Flow?
As of today (2024-05-06), ENDRA Life Sciences's share price is $0.3267.
ENDRA Life Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.76. Hence, ENDRA Life Sciences's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for ENDRA Life Sciences's Price-to-Operating-Cash-Flow or its related term are showing as below:
ENDRA Life Sciences's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.25.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.76.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 48.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 45.60% per year.
During the past 10 years, ENDRA Life Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 48.80% per year. The lowest was -10.20% per year. And the median was 22.40% per year.
ENDRA Life Sciences Price-to-Operating-Cash-Flow Historical Data
The historical data trend for ENDRA Life Sciences's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences Price-to-Operating-Cash-Flow Chart
|
ENDRA Life Sciences Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
ENDRA Life Sciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of ENDRA Life Sciences's Price-to-Operating-Cash-Flow
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Price-to-Operating-Cash-Flow falls into.
ENDRA Life Sciences Price-to-Operating-Cash-Flow Calculation
ENDRA Life Sciences's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.3267 | / | -1.761 |
| = | |
ENDRA Life Sciences's Share Price of today is $0.3267.
ENDRA Life Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
| Michael Milos Thornton |
officer: Chief Technology Officer |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Anthony Digiandomenico |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Alexander Y Tokman |
director |
C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
| Francois Roger Michelon |
director, officer: Chief Executive Officer |
430 N. JUNO LANE, JUNO BEACH FL 33406 |
| Lou Basenese |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Irina Pestrikova |
officer: Senior Director, Finance |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Renaud Bertrand Maloberti |
officer: Chief Commercial Officer |
10 ACORN WAY, GEORGETOWN MA 01833 |
| David R. Wells |
officer: Chief Financial Officer |
2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
| Michael Harsh |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Longboard Capital Advisors, Llc |
10 percent owner |
9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
| Brett Conrad |
10 percent owner |
1312 CEDAR ST., SANTA MONICA CA 90405 |
| Sanjiv Sam Gambhir |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
ENDRA Life Sciences (ENDRA Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your